window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

NLRP3 inflammasome

  • Biotech,Clinical Development,Clinical Trials,Drug Development,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764

    AC Immune has initiated a Phase 1 trial of its [...]

    February 24, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ProQR partners with Ginkgo Bioworks for AI-driven RNA editing development and forms advisory board
    Categories: Artificial Intelligence, Biotech, Drug Development, Drug discovery, Research & Development
  • Weite Oldenziel
    Ofichem unifies CDMO and pharmaceutical supply brands under single identity
    Categories: CDMOs & Manufacturing, Supply Chain & Logistics
  • DeepCyte raises $1.5M to advance single-cell AI toxicology platform for drug development
    Categories: Artificial Intelligence, Drug discovery, Funding, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top